Role of advanced glycation end products in hypertension and cardiovascular risk: human studies.

[1]  Hiroshi Kobayashi,et al.  Peripheral RAGE (receptor for advanced glycation endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response. , 2012, Journal of reproductive immunology.

[2]  Sungeun Kim,et al.  Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. , 2012, Atherosclerosis.

[3]  A. Rendon,et al.  Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis , 2012, BMC Infectious Diseases.

[4]  G. Hitman,et al.  Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes , 2011, Diabetes.

[5]  C. DeCarli,et al.  Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). , 2011, Atherosclerosis.

[6]  K. Hirata,et al.  Increased levels of HMGB-1 and endogenous secretory RAGE in induced sputum from asthmatic patients. , 2011, Respiratory medicine.

[7]  T. Shang,et al.  Calprotectin, RAGE and TNF-α in hypertensive disorders in pregnancy: expression and significance , 2011, Archives of Gynecology and Obstetrics.

[8]  H. Parving,et al.  Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes , 2011, Diabetes Care.

[9]  A. Vianello,et al.  Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. , 2010, Atherosclerosis.

[10]  D. J. Veldhuisen,et al.  Advanced glycation end‐products, anti‐hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction , 2010, European journal of heart failure.

[11]  F. Gao,et al.  Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage. , 2010, Diabetes research and clinical practice.

[12]  T. Sawamura,et al.  Evidence for Increased Methylglyoxal in the Vasculature of Women With Preeclampsia: Role in Upregulation of LOX-1 and Arginase , 2009, Hypertension.

[13]  J. Staessen,et al.  Association between carotid diameter and the advanced glycation endproduct Nε-Carboxymethyllysine (CML) , 2009, Cardiovascular diabetology.

[14]  C. Schalkwijk,et al.  Advanced Glycation End Products Accumulate in Vascular Smooth Muscle and Modify Vascular but Not Ventricular Properties in Elderly Hypertensive Canines , 2008, Circulation.

[15]  S. Yamagishi,et al.  Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation. , 2008, Protein and peptide letters.

[16]  G. Wolf,et al.  Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension , 2008, Nephron Clinical Practice.

[17]  A. Smit,et al.  Clinical and prognostic value of advanced glycation end-products in chronic heart failure. , 2007, European heart journal.

[18]  F. Santilli,et al.  Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. , 2007, Free radical biology & medicine.

[19]  M. Esiri,et al.  Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia , 2007, BMC neurology.

[20]  M. Laakso,et al.  Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study , 2007, Diabetologia.

[21]  M. Hersberger,et al.  Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. , 2007, European heart journal.

[22]  Azra Mahmud,et al.  Advanced glycation end-products and arterial stiffness in hypertension. , 2007, American journal of hypertension.

[23]  N. Traverso,et al.  Effects of valsartan therapy on protein glycoxidation. , 2006, Metabolism: Clinical and Experimental.

[24]  T. Imaizumi,et al.  Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes , 2006, Clinical and Experimental Medicine.

[25]  H. Parving,et al.  Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria , 2006, Diabetes.

[26]  H. Hirose,et al.  Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. , 2006, Diabetes research and clinical practice.

[27]  L. Hunsicker,et al.  The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension , 2006 .

[28]  L. Leng,et al.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes , 2006, Diabetologia.

[29]  J. Nagy,et al.  Serum carboxymethyllysine predicts mortality in hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  T. Imaizumi,et al.  Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. , 2005, Microvascular research.

[31]  A. D'Angelo,et al.  Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.

[32]  S. Jacqueminet,et al.  Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. , 2005, Clinical chemistry.

[33]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[34]  N. Chaturvedi,et al.  Advanced Glycation End Products Are Associated With Pulse Pressure in Type 1 Diabetes: The EURODIAB Prospective Complications Study , 2005, Hypertension.

[35]  D. Stern,et al.  Advanced Glycation End Product Receptor‐Mediated Cellular Dysfunction , 2005, Annals of the New York Academy of Sciences.

[36]  M. Laakso,et al.  High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men: A Population-Based 18-Year Follow-Up Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[37]  R. Ramasamy,et al.  Protein Glycation: A Firm Link to Endothelial Cell Dysfunction , 2004, Circulation research.

[38]  G. Lang,et al.  Elevated serum levels of Nε-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema , 2004, Diabetologia.

[39]  C. Schalkwijk,et al.  N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. , 2004, Atherosclerosis.

[40]  M. Huijberts,et al.  N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. , 2003, Diabetes & metabolism.

[41]  C. Wanner,et al.  Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.

[42]  W. Schady,et al.  Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial , 1998, The Lancet.

[43]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[44]  K. Ikeda,et al.  Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. , 1997, The Journal of investigative dermatology.

[45]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[46]  Sungha Park,et al.  Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. , 2012, Atherosclerosis.

[47]  M. Prins,et al.  Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study , 2009, Diabetologia.

[48]  L. Ferrucci,et al.  Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. , 2009, American journal of hypertension.

[49]  G. Basta.  Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. , 2008, Atherosclerosis.

[50]  D. Schocken,et al.  Cardiovascular Diabetology BioMed Central Original investigation Increased proinflammatory endothelial response to S100A8/A9 , 2006 .

[51]  L Guize,et al.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.